What Is Nonvalvular Afib? Symptoms And Treatment

Atrial fibrillation is the most common heart rhythm disorder in adults. The term “nonvalvular” describes AFib that is not caused by a problem with the heart’s mitral valve. This distinction matters because it affects how doctors think about stroke risk and which blood thinners they consider. Nonvalvular AFib is the type most people have — roughly 90 percent of AFib cases fall into this category. It means the irregular heartbeat comes from the heart’s electrical system misfiring, not from a damaged or leaking valve.

What Is Nonvalvular Afib and How Is It Different From Other Types?

Nonvalvular atrial fibrillation is an irregular, often rapid heart rhythm that starts in the upper chambers of the heart — the atria — when there is no significant disease of the mitral valve driving it.

In a normal heart, the sinoatrial node sends a clean electrical signal that makes the atria contract and push blood into the lower chambers. In AFib, that signal gets scrambled. Multiple chaotic electrical impulses fire across the atria at once. The atria quiver instead of contracting properly. Blood can pool in a small pouch called the left atrial appendage, and pooled blood is where clots form.

The “nonvalvular” label is not about how severe the AFib is. It is a classification based on the underlying cause. AFib that occurs with moderate-to-severe mitral stenosis or with a mechanical heart valve is called valvular AFib. That distinction changes treatment. People with valvular AFib generally need warfarin, a specific older blood thinner. People with nonvalvular AFib have more options, including newer anticoagulants.

This classification has shifted over time. The definition has been refined as evidence accumulated, and some clinicians now use the term more broadly than others. If you have AFib and a valve condition, ask your cardiologist which category you fall into — it directly affects your medication choices.

What Causes Nonvalvular Afib?

Age is the single strongest risk factor. The older you get, the more likely the heart’s electrical system is to misfire. But age alone does not cause it in everyone.

Common contributing conditions include:

• High blood pressure — the most common modifiable risk factor
• Coronary artery disease
• Heart failure
• Overactive thyroid
• Sleep apnea
• Diabetes
• Obesity
• Excess alcohol use

Sometimes AFib happens with no identifiable cause. That is called lone AFib, and it is more common in younger people. Sometimes it is triggered by acute situations — surgery, infection, or heavy drinking — and may not recur.

The mechanism behind most nonvalvular AFib involves changes in the atrial tissue itself. Over time, fibrosis (scarring) and inflammation can disrupt the normal electrical pathways. This is why treating underlying conditions like high blood pressure and sleep apnea matters — they feed the process that makes AFib worse.

What Are the Symptoms of Nonvalvular Afib?

Some people feel nothing. Others feel like their heart is racing, fluttering, or skipping beats. That range is real and it is wide.

Common symptoms include:

• Palpitations — a fluttering, pounding, or irregular heartbeat
• Fatigue, especially with activity
• Shortness of breath
• Dizziness or lightheadedness
• Chest discomfort
• Reduced ability to exercise

A significant number of people with AFib have no symptoms at all. The condition is sometimes found during a routine exam or on an ECG done for another reason. This is called silent AFib, and it still carries stroke risk.

Symptoms can come and go. Paroxysmal AFib starts and stops on its own, usually within a week. Persistent AFib lasts longer than a week and often needs treatment to restore normal rhythm. Long-standing persistent AFib has continued for more than a year. Permanent AFib is when the rhythm is accepted as ongoing and attempts to restore normal rhythm have stopped.

The pattern matters for treatment decisions, but it does not change the stroke risk by itself. Stroke risk is driven mainly by other factors like age, blood pressure, and prior stroke.

How Is Nonvalvular Afib Diagnosed?

An electrocardiogram (ECG) confirms the diagnosis. It records the heart’s electrical activity and shows the characteristic irregular pattern of AFib — no consistent P waves and an irregularly irregular ventricular rate.

But AFib that comes and goes can be hard to catch. A standard ECG only captures a few seconds. If your symptoms are intermittent, your doctor may recommend:

• A Holter monitor — a portable ECG worn for 24 to 48 hours
• An event monitor — worn for weeks or months, activated when symptoms occur
• An implantable loop recorder — a small device placed under the skin that continuously records for up to several years
• Consumer heart rate monitors or smartwatch ECG features — useful for detecting possible AFib, but not a substitute for a clinical ECG

Once AFib is confirmed, your doctor will assess stroke risk using a scoring system. The most widely used is the CHA₂DS₂-VASc score, which assigns points for conditions like heart failure, high blood pressure, age, diabetes, and prior stroke. Higher scores mean higher stroke risk and a stronger reason to consider blood thinners.

Blood tests check thyroid function, kidney function, and electrolyte levels. An echocardiogram looks at heart structure and function, and helps confirm whether the mitral valve is involved — which determines whether the AFib is classified as valvular or nonvalvular.

How Is Nonvalvular Afib Treated?

Treatment has two main goals: prevent stroke and control the heart rhythm or rate. These are separate decisions and both matter.

Stroke prevention is the priority. For people with nonvalvular AFib and enough risk factors, anticoagulants (blood thinners) reduce stroke risk. Options include direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran, and the older drug warfarin. DOACs are generally preferred for nonvalvular AFib because they do not require routine blood monitoring and have fewer food and drug interactions than warfarin. Warfarin remains the required choice for people with mechanical heart valves or moderate-to-severe mitral stenosis.

Not everyone with AFib needs an anticoagulant. The decision depends on the balance of stroke risk versus bleeding risk. This is a conversation to have with your doctor, not a decision to make on your own.

Rate control means slowing the heart rate without trying to restore normal rhythm. Medications like beta-blockers or calcium channel blockers are commonly used. The target resting heart rate is usually under 100 to 110 beats per minute, though this varies by patient.

Rhythm control means trying to restore and maintain normal sinus rhythm. Options include:

• Electrical cardioversion — a controlled shock that resets the heart rhythm
• Antiarrhythmic medications such as flecainide, sotalol, or amiodarone
• Catheter ablation — a procedure that destroys the small areas of heart tissue generating the abnormal signals

Whether rate control or rhythm control is better has been studied extensively. For many years, rate control was considered adequate for most patients. More recent evidence suggests that early rhythm control may offer advantages in certain groups, particularly younger patients and those with recent-onset AFib. The evidence here is still evolving, and the best approach depends on individual factors.

Catheter ablation has become more common and is often effective, especially for paroxysmal AFib. It is not a guaranteed cure. Some people need a second procedure. Some still need medication afterward.

What Is the Stroke Risk With Nonvalvular Afib?

AFib raises stroke risk substantially. The irregular rhythm allows blood to pool in the left atrial appendage, where clots can form and then travel to the brain.

How much risk a person carries depends on their individual factors, not just the diagnosis. A 45-year-old with AFib and no other conditions has a much lower stroke risk than a 75-year-old with high blood pressure and diabetes. That is why risk scoring systems exist — they help doctors decide who benefits from anticoagulation.

Anticoagulation reduces stroke risk in nonvalvular AFib. That is one of the most well-established findings in cardiology. But blood thinners also increase bleeding risk, including the risk of bleeding in the brain. The decision to use them is always a balance.

One non-obvious point: aspirin is no longer recommended as a substitute for anticoagulation in most people with nonvalvular AFib. It was used that way for years, but evidence showed it provides little stroke protection while still carrying bleeding risk. Current guidance favors either an anticoagulant or no blood thinner at all, depending on risk level, rather than aspirin as a middle ground.

Can Nonvalvular Afib Be Prevented?

Not all cases can be prevented. Age and genetics are not modifiable. But several risk factors are.

Blood pressure control is the most impactful step. Keeping blood pressure in a healthy range reduces the strain on the heart’s electrical system. Regular physical activity, maintaining a healthy weight, and treating sleep apnea also matter.

Alcohol is a well-known trigger. Heavy drinking increases the chance of an AFib episode, and even moderate drinking may raise risk over time. Reducing or eliminating alcohol can help some people.

Managing conditions like diabetes and thyroid disease, and treating sleep apnea, address pathways that contribute to atrial remodeling — the structural changes that make AFib more likely to persist.

No lifestyle change guarantees prevention. But the evidence consistently supports these steps as reducing risk and improving outcomes in people who already have AFib.